


Noise Figure Analysis Fully Differential Amplifier

National Semiconductor
Application Note 1719
Robert Malone, Mike Ewer
September 2007



Fully Differential Feedback Amplifiers (FDA) such as National's LMH6550, LMH6551 and the newly released LMH6552 are used to provide balanced low distortion amplification and level shifting to wide bandwidth differential signals. A simplified conceptual diagram of an FDA is shown in Figure 1 where two forward paths amplify the two comple-

mentary halves of the differential signal. A separate common mode feedback circuit controlled by the V_{CM} control input sets the output common mode voltage independent of the input common mode, as well as forcing the O_N and O_P outputs to be equal in magnitude and opposite in phase.



$$V_{OUT} = V_{IN} \frac{R_F}{R_G}$$

Where

$$R_F = R_{F1} = R_{F2}$$

$$R_G = R_{G1} = R_{G2}$$

30038201

FIGURE 1. Simplified Conceptual Diagram of Fully Differential Amplifier

The LMH6552 FDA is a 1.5 GHz device using National's proprietary differential Current Feedback (CFB) architecture to allow operation at gains greater than unity with exceptional gain flatness, and without sacrificing bandwidth. With 450 MHz of 0.1 dB unity gain flatness the device is ideally suited to driving a range of 8- to 14-bit high-speed ADCs, including National's Giga Sample 8 bit family and the ADC14DS105, in a variety of wideband Nyquist applications.

In designing an FDA to drive an ADC it is required to ensure that the FDA does not degrade the ADC's signal to noise and distortion (SINAD) performance. A key element of this anal-

ysis is determining and optimizing the noise performance of the FDA. The remainder of this article will show how the FDA output noise spectral density and noise figure can be calculated for factoring into the overall system noise analysis. Voltage Feedback (VFB) FDAs have historically been constrained to operating at low gain due to their poor noise performance at higher gains. This article will show that the LMH6552 CFB architecture overcomes this constraint, delivering a noise advantage as well as a gain bandwidth advantage over alternative VFB devices.




FIGURE 2. Fully Differential Amplifier Noise Model

Output Noise Calculation for Fully Differential Amplifiers

The noise model for a general purpose FDA is shown in Figure 2. I_{NP} and I_{NM} are the input referred noise currents for the FDA’s positive and negative input terminals respectively, and V_N is its input referred noise voltage. Included in the model are noise sources associated with resistive elements in the feedback and source termination networks.

The total output referred noise density V_{NO} in nV/\sqrt{Hz} , is calculated by taking the root square sum (rss) of the output referred noise from each source in the model. Since we are primarily interested in how noise internal to the FDA influences overall system noise performance, we separate the equation for V_{NO} into two components; the first being due to the input referred noise from the FDA, V_{NOFDA} , and the second due to thermal noise from the resistive feedback network, V_{NOFB} .

$$\overline{V_{NO}} = \sqrt{\overline{V_{NOFDA}}^2 + \overline{V_{NOFB}}^2}$$

In most differential signaling applications CMRR and balance error are key. The differential feedback network is balanced by selecting $R_{F1}=R_{F2}=R_F$ and $R_{G1}=R_{G2}=R_G$, so both positive and negative feedback factors are matched and symmetric. Replacing R_S and R_T with their Thevenin equivalent source resistance, $R_{S_{TH}}=R_S \parallel R_T$, the FDA and feedback network output noise densities are:

$$\overline{V_{NOFDA}}^2 = \overline{V_N}^2 \left(\frac{R_F + R_{G_{EQ}}}{R_{G_{EQ}}} \right)^2 + \overline{I_{NP}}^2 R_F^2 + \overline{I_{NM}}^2 R_F^2 \tag{1}$$

$$\overline{V_{NOFB}}^2 = 4kT(2R_F) + 4kT(2R_G) \left(\frac{R_F}{R_{G_{EQ}}} \right)^2 + 4kTR_S(R_{S_{TH}}) \left(\frac{R_F}{R_{G_{EQ}}} \right)^2$$

$$R_{G_{EQ}} = R_G + \frac{R_S \parallel R_T}{2} \tag{2}$$

The impact of external resistor noise is determined by the differential feedback topology (Equation 1), regardless of whether a CFB or VFB FDA is chosen. However, the influence

of the FDA on total output noise density can largely be influenced by the choice of FDA architecture.

In a VFB FDA, the differential input impedance is very high (usually hundreds of $K\Omega$ to several $M\Omega$), and noise sources internal to the FDA will tend to refer to the input as voltages. Consequently, input referred noise currents will be quite small, on the order of a few pA/\sqrt{Hz} , and will only contribute a significant portion of the total output noise when R_F is large, which is usually not the case. Note that the gain term for V_N in is simply the reciprocal of the equivalent feedback factor β_{EQ} which is related to the differential amplifier’s closed loop gain G by:

$$G = \frac{R_F}{R_{G_{EQ}}} = \frac{1}{\beta_{EQ}} - 1.$$

Neglecting I_{NP} and I_{NM} , can be re-written as:

$$\overline{V_{NOFDA}}^2 \cong \overline{V_N}^2 (G + 1)^2$$

In other words, operating a VFB FDA at high values of gain is necessarily accompanied by a proportional increase in output noise density, and can lead to degradation of overall noise performance when the FDA is a significant source of noise in a system.

A very different result arises when a CFB FDA, such as the LMH6552, is considered. Here, the differential input stage is essentially a current controlled current source, with ideally zero differential input impedance. As a consequence noise sources internal to the amplifier tend to refer to the inputs as currents, rather than as voltages, and the total FDA output noise will be dominated by the sum of input noise currents I_{NP} and I_{NM} multiplied by the feedback resistor squared.

$$\overline{V_{NOFDA}}^2 \cong \left(\overline{I_{NP}}^2 + \overline{I_{NM}}^2 \right) R_F^2$$


Unlike a VFB FDA, the output noise of a CFB FDA depends on the value of R_F rather than on the amplifier's gain. Hence, increasing the gain by reducing R_G does not appreciably degrade the noise performance of the circuit. This is an extremely important result and highlights one of the key advantages of using a CFB FDA over a VFB FDA in differential signaling applications.

Noise Figure Calculation for Fully Differential Amplifiers

In many high-speed systems, noise performance is often described in terms of the system noise figure, which is 10 log of the signal-to-noise ratio at the system's input divided by the signal to noise ratio at its output. Noise figure is a quantitative measure of how much noise is added to a given signal as it propagates through a processing chain, and for amplifiers can be conveniently expressed as the ratio of output noise density to source noise density by the following equation.


$$NF = 10 \log \left(\frac{\overline{V_{NO}}^2}{4kTR_sG^2D_T^2} \right); \quad D_T = \frac{R_T}{R_S + R_T}$$

The product GD_T is the voltage gain of the amplifier from V_S to V_O including the signal attenuation of the input termination network.



30038210

FIGURE 3. Noise Analysis Example for $A_v=1$



30038211

FIGURE 4. Noise Figure and Voltage Noise Spectral Density vs Gain

To highlight the difference in noise performance between CFB and VFB FDAs, the application circuit of *Figure 3* is used to calculate the output noise spectral density and noise figure at various values of gain using both the LMH6552 (CFB) and LMH6550 (VFB) FDAs in a 100Ω system. R_F is held at 301Ω and the termination resistor R_T is adjusted at each value of gain to maintain a 100Ω differentially terminated input. The results are presented graphically in *Figure 4*.

At low gain, the two parts offer similar noise performance, with the LMH6552 having a roughly 2 dB edge in noise figure at a gain of -6 dB. However, as gain is increased, the CFB FDA's noise figure improves at a substantially higher rate, giving a 6.5 dB improvement at a gain of 9.5 dB.

Conclusion

The choice between a current or voltage mode FDA may depend on many factors and will ultimately come down to which amplifier works better within a given system specification. Where low-noise, wide-bandwidth applications require the FDA to be configured for larger than unity gain CFB FDAs can offer an elegant solution.

Notes

THE CONTENTS OF THIS DOCUMENT ARE PROVIDED IN CONNECTION WITH NATIONAL SEMICONDUCTOR CORPORATION ("NATIONAL") PRODUCTS. NATIONAL MAKES NO REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE ACCURACY OR COMPLETENESS OF THE CONTENTS OF THIS PUBLICATION AND RESERVES THE RIGHT TO MAKE CHANGES TO SPECIFICATIONS AND PRODUCT DESCRIPTIONS AT ANY TIME WITHOUT NOTICE. NO LICENSE, WHETHER EXPRESS, IMPLIED, ARISING BY ESTOPPEL OR OTHERWISE, TO ANY INTELLECTUAL PROPERTY RIGHTS IS GRANTED BY THIS DOCUMENT.

TESTING AND OTHER QUALITY CONTROLS ARE USED TO THE EXTENT NATIONAL DEEMS NECESSARY TO SUPPORT NATIONAL'S PRODUCT WARRANTY. EXCEPT WHERE MANDATED BY GOVERNMENT REQUIREMENTS, TESTING OF ALL PARAMETERS OF EACH PRODUCT IS NOT NECESSARILY PERFORMED. NATIONAL ASSUMES NO LIABILITY FOR APPLICATIONS ASSISTANCE OR BUYER PRODUCT DESIGN. BUYERS ARE RESPONSIBLE FOR THEIR PRODUCTS AND APPLICATIONS USING NATIONAL COMPONENTS. PRIOR TO USING OR DISTRIBUTING ANY PRODUCTS THAT INCLUDE NATIONAL COMPONENTS, BUYERS SHOULD PROVIDE ADEQUATE DESIGN, TESTING AND OPERATING SAFEGUARDS.

EXCEPT AS PROVIDED IN NATIONAL'S TERMS AND CONDITIONS OF SALE FOR SUCH PRODUCTS, NATIONAL ASSUMES NO LIABILITY WHATSOEVER, AND NATIONAL DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY RELATING TO THE SALE AND/OR USE OF NATIONAL PRODUCTS INCLUDING LIABILITY OR WARRANTIES RELATING TO FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, OR INFRINGEMENT OF ANY PATENT, COPYRIGHT OR OTHER INTELLECTUAL PROPERTY RIGHT.

LIFE SUPPORT POLICY

NATIONAL'S PRODUCTS ARE NOT AUTHORIZED FOR USE AS CRITICAL COMPONENTS IN LIFE SUPPORT DEVICES OR SYSTEMS WITHOUT THE EXPRESS PRIOR WRITTEN APPROVAL OF THE CHIEF EXECUTIVE OFFICER AND GENERAL COUNSEL OF NATIONAL SEMICONDUCTOR CORPORATION. As used herein:

Life support devices or systems are devices which (a) are intended for surgical implant into the body, or (b) support or sustain life and whose failure to perform when properly used in accordance with instructions for use provided in the labeling can be reasonably expected to result in a significant injury to the user. A critical component is any component in a life support device or system whose failure to perform can be reasonably expected to cause the failure of the life support device or system or to affect its safety or effectiveness.

National Semiconductor and the National Semiconductor logo are registered trademarks of National Semiconductor Corporation. All other brand or product names may be trademarks or registered trademarks of their respective holders.

Copyright© 2007 National Semiconductor Corporation

For the most current product information visit us at www.national.com



National Semiconductor Americas Customer Support Center
 Email: new.feedback@nsc.com
 Tel: 1-800-272-9959

National Semiconductor Europe Customer Support Center
 Fax: +49 (0) 180-530-85-86
 Email: europe.support@nsc.com
 Deutsch Tel: +49 (0) 69 9508 6208
 English Tel: +49 (0) 870 24 0 2171
 Français Tel: +33 (0) 1 41 91 8790

National Semiconductor Asia Pacific Customer Support Center
 Email: ap.support@nsc.com

National Semiconductor Japan Customer Support Center
 Fax: 81-3-5639-7507
 Email: jpn.feedback@nsc.com
 Tel: 81-3-5639-7560